<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513028</url>
  </required_header>
  <id_info>
    <org_study_id>20.0614</org_study_id>
    <nct_id>NCT04513028</nct_id>
  </id_info>
  <brief_title>Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma</brief_title>
  <official_title>Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kelly McMasters</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how beta-glucan affects the immune system in&#xD;
      subjects with melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a clinical pilot study using oral beta-glucan on patients with advanced stage III-IV&#xD;
      melanoma without evidence of disease receiving adjuvant Pembrolizumab. The aim is to see&#xD;
      whether beta-glucan treatment in combination with Pembrolizumab may provide augmented&#xD;
      immunologic phenotypes such as decreased peripheral MDSCs, enhanced T effector cell function,&#xD;
      or enhanced cytokine production in the peripheral blood or plasm of enrolled subjects.&#xD;
      Secondary outcome measures will include clinical endpoints such as recurrence, progression&#xD;
      free survival and overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in percent of lymphocyte cell surface expression markers</measure>
    <time_frame>Blood for analysis will be drawn at baseline (Day 0), 3 weeks post pembrolizumab treatment, and 3 weeks post pembrolizumab plus oral beta-glucan treatment.</time_frame>
    <description>The investigators will quantify percent of lymphocyte cell surface e (i.e., CD45, CD3, CD11b, etc.) from each sample collected by mass cytometry *CyTOF) or flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in absolute number of lymphocyte cell surface expression markers</measure>
    <time_frame>Blood for analysis will be drawn at baseline (Day 0), 3 weeks post pembrolizumab treatment, and 3 weeks post pembrolizumab plus oral beta-glucan</time_frame>
    <description>The investigators will quantify absolute number of lymphocyte cell surface (i.e., CD45, CD3, CD11b, etc.) from each sample collected by mass cytometry (CyTOF) or flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the mean fluorescent intensity of lymphocyte cell surface expression markers</measure>
    <time_frame>Blood for analysis will be drawn at baseline (Day 0), 3 weeks post pembrolizumab treatment, and 3 weeks post pembrolizumab plus oral beta-glucan</time_frame>
    <description>The investigators will quantify mean fluorescent intensity of lymphocyte cell surface (i.e., CD45, CD3, CD11b, etc.) from each sample collected by mass cytometry *CyTOF) or flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in percent of intracellular cytokine expression markers</measure>
    <time_frame>Blood for analysis will be drawn at baseline (Day 0), 3 weeks post pembrolizumab treatment, and 3 weeks post pembrolizumab plus oral beta-glucan</time_frame>
    <description>The investigators will quantify percent of intracellular cytokine expression (TNFa, IFNg, etc.) from each sample collected by mass cytometry (CyTOF) or flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in absolute number of intracellular cytokine expression markers</measure>
    <time_frame>Blood for analysis will be drawn at baseline (Day 0), 3 weeks post pembrolizumab treatment, and 3 weeks post pembrolizumab plus oral beta-glucan</time_frame>
    <description>The investigators will quantify absolute number of intracellular cytokine expression (TNF-a, IFNg, etc.) from each sample collected by mass cytometry (CyTOF) or flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in fluorescent intensity of intracellular cytokine expression markers</measure>
    <time_frame>Blood for analysis will be drawn at baseline (Day 0), 3 weeks post pembrolizumab treatment, and 3 weeks post pembrolizumab plus oral beta-glucan</time_frame>
    <description>The investigators will quantify fluorescent intensity of intracellular cytokine expression (TNF-a, IFNg, etc.) from each sample collected by mass cytometry (CyTOF) or flow cytometry</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Melanoma Stage III</condition>
  <condition>Melanoma Stage IV</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo 21 days of Pembrolizumab followed by 21 days of beta-glucan.&#xD;
Pembrolizumab: 200 mg/100mL IV in three week intervals&#xD;
Beta-glucan: 500mg (1 capsule) by mouth twice a day for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Beta-Glucan</intervention_name>
    <description>500mg (1 capsule) by mouth twice a day for 21 days.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patients with suspected (clinical) or definitive (tissue) diagnosis of Stage&#xD;
             III-IV melanoma starting or continuing adjuvant Pembrolizumab without active evidence&#xD;
             of disease (NED).&#xD;
&#xD;
          -  Must be treatment na√Øve or have had treatment no less than 6 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Must be able to take pills&#xD;
&#xD;
          -  ECOG performance status of 0-3&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent&#xD;
&#xD;
          -  Members of all racial and ethnic groups are eligible for this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity reactions attributed to beta-glucan&#xD;
&#xD;
          -  Patients receiving continuous or other ongoing immunosuppressive therapy&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, autoimmune diseases,&#xD;
             ongoing or active infection, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          -  Any patients who have serious autoimmune toxicity during the study period, or those&#xD;
             who have disease recurrence during the 6-week study period should be excluded and&#xD;
             analyzed separately&#xD;
&#xD;
          -  Patients with mucosal melanoma&#xD;
&#xD;
          -  Patients with concurrent malignancy or recent history thereof&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly M McMasters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Woeste, MD</last_name>
    <phone>502-852-0325</phone>
    <email>matthew.woeste@louisville.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Woeste, MD</last_name>
      <phone>502-852-0325</phone>
      <email>matthews.woeste@louisville.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Kelly McMasters</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

